Anti-angiogenic therapies in cancer clinical trials.

about

Current status of antiangiogenic factors.Angiogenic and antiangiogenic gene therapy.In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.The Characteristics of Vascular Growth in VX2 Tumor Measured by MRI and Micro-CT.

P2860

Q33962049-9F53FBDB-4698-4E81-B0E8-3D9854553FBF Q36288905-6BD2DDF2-E791-4B89-A6DE-7213E66A8920 Q36610372-97E7BBCC-DCBE-4C69-8E15-4AB30B5ED31A Q38445434-9D7BEE0C-9D43-47DF-BC27-CC6F0CF54CF7

P2860

Anti-angiogenic therapies in cancer clinical trials.

Item

http://www.wikidata.org/entity/Q36181120

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Anti-angiogenic therapies in cancer clinical trials.

@ast

Anti-angiogenic therapies in cancer clinical trials.

@en

type

Item

label

Anti-angiogenic therapies in cancer clinical trials.

@ast

Anti-angiogenic therapies in cancer clinical trials.

@en

prefLabel

Anti-angiogenic therapies in cancer clinical trials.

@ast

Anti-angiogenic therapies in cancer clinical trials.

@en

P1476

Anti-angiogenic therapies in cancer clinical trials

@en

P2093

H T Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Squalamine: an aminosterol antibiotic from the shark

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Phase I trial of pentosan polysulfate.

Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma.

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.

Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs.

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail.

P304

1629-1655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.7.10.1629

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

P577

1998-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15991906

http://www.w3.org/2001/XMLSchema#string

Anti-angiogenic therapies in cancer clinical trials.

about

P2860

P2860

Anti-angiogenic therapies in cancer clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698